

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

## **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board announces that Mr. LIN Sheng has resigned as a non-executive director of the Company with effect from 13 April 2018.

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) announces that Mr. LIN Sheng (“**Mr. LIN**”) has resigned from the position of the non-executive director of the Company with effect from 13 April 2018 to further develop his own business.

Mr. LIN has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. LIN towards the Company during his tenure of office.

By order of the Board of  
**Consun Pharmaceutical Group Limited**  
**AN Yubao**  
*Chairman*

Hong Kong, 13 April 2018

*As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive directors.*